A phase II evaluation of trastuzumab (MoAb HER2) in patients with advanced, recurrent or persistent endometrial carcinoma with or without prior chemotherapy
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2014
At a glance
- Drugs Trastuzumab (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Aug 2005 New trial record.